Cargando…

The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation

The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs. These effects were ascribed to the effects of eltrombopag on megakaryocytes. Here, we tested whether eltrombopag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogel, Jens-Uwe, Schmidt, Sophie, Schmidt, Daniel, Rothweiler, Florian, Koch, Benjamin, Baer, Patrick, Rabenau, Holger, Michel, Detlef, Stamminger, Thomas, Michaelis, Martin, Cinatl, Jindrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017049/ https://www.ncbi.nlm.nih.gov/pubmed/31861948 http://dx.doi.org/10.3390/cells9010031

Ejemplares similares

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
por: Erickson-Miller, Connie L, et al.
Publicado: (2009)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma
por: Jeong, Jee-Yeong, et al.
Publicado: (2015)

Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
por: Morgenstern, Birgit, et al.
Publicado: (2005)

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
por: Cai, Xuan, et al.
Publicado: (2022)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication
por: Waters, Torin, et al.
Publicado: (2020)

Correlation of inflammatory and proangiogenic cytokines from undiluted vitreous samples with spectral domain OCT scans, in untreated branch retinal vein occlusion
por: Pfister, Marcel, et al.
Publicado: (2013)

Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status
por: Michaelis, Martin, et al.
Publicado: (2015)

Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2
por: Michaelis, Martin, et al.
Publicado: (2019)

Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach
por: Sarin, Navin, et al.
Publicado: (2018)

Investigation of the influence of EPs(®) 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses
por: Michaelis, Martin, et al.
Publicado: (2011)

Selection of a highly invasive neuroblastoma cell population through long-term human cytomegalovirus infection
por: Michaelis, M, et al.
Publicado: (2012)

Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia
por: Argenziano, Maura, et al.
Publicado: (2021)

Intrinsic Immune Mechanisms Restricting Human Cytomegalovirus Replication
por: Schilling, Eva-Maria, et al.
Publicado: (2021)

Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019)

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice
por: Nakai, Kensaku, et al.
Publicado: (2022)

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia
por: Bastida, José María, et al.
Publicado: (2021)

ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance
por: Löschmann, Nadine, et al.
Publicado: (2016)

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
por: Zhu, Qiuhua, et al.
Publicado: (2021)

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
por: Punzo, Francesca, et al.
Publicado: (2018)

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
por: Garzon, Angelica Maria, et al.
Publicado: (2015)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
por: Nilles, Kathy M., et al.
Publicado: (2019)

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
por: Michaelis, Martin, et al.
Publicado: (2014)

Immune thrombocytopenia secondary to primary cytomegalovirus infection after renal transplantation treated with a thrombopoietin receptor agonist: a case report
por: Takehara, Tomohiro, et al.
Publicado: (2023)

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
por: Shin, Jiwon, et al.
Publicado: (2023)

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression
por: Michaelis, Martin, et al.
Publicado: (2014)

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
por: Yamamoto, Norio, et al.
Publicado: (2004)

PB2425: EFFICACY AND SAFETY OF COMBINED THERAPY OF RECOMBINANT HUMAN THROMBOPOIETIN AND ELTROMBOPAG FOR TREATMENT OF PERSISTENT THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pan, Pan, et al.
Publicado: (2023)

BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells
por: Das, Chandan Kanta, et al.
Publicado: (2018)

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting
por: Michaelis, Martin, et al.
Publicado: (2020)

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
por: Michaelis, Martin, et al.
Publicado: (2020)

Increased HRD score in cisplatin resistant penile cancer cells
por: Winkelmann, Ria, et al.
Publicado: (2022)

A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists
por: Khan, Meaghan, et al.
Publicado: (2010)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019)

Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists
por: Gilreath, Jeffrey, et al.
Publicado: (2021)

Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
por: Widera, Marek, et al.
Publicado: (2021)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
por: Cinatl, J, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_v00iqmchqmd6c0gbfb2luov452